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Summary Six groups of inbred male Wistar/Furth (WF) rats were castrated at 40 days of age and group I
received no further treatment. Groups 3 and 5 received 5.0mg diethylstilboestrol (DES) pellets. Groups 4 and
6 were given both DES and 5.0mg anti-oestrogen (antiE) clomiphene citrate pellets. At 50-55 days of age
groups 2, 5, and 6 were exposed daily to drinking water containing 5.0mg N-nitrosobutylurea (NBU), for 30
days. None of the castrated rats or castrated rats given NBU alone developed mammary or pituitary tumours
(MT, PT). When antiE was administered, both MT and PT incidences were reduced in rats given DES alone
or in combination with NBU. Furthermore, in antiE-treated rats receiving DES and NBU the mean number
of MT per rat was also significantly decreased. Similarly a marked reduction in the mean pituitary weight was
observed in antiE-treated groups. These results indicate that antiE treatment was effective in the prevention of
both mammary and pituitary tumorigenesis in rats receiving DES alone or receiving a combination of DES
and NBU, and its inhibitory effect on mammary tumorigenesis may be mainly due to competitive antagonism
for DES-induced pituitary tumorigenesis by antiE.
Anti-oestrogen (antiE) has been known to mimic
oestrogenic action and to prevent oestrogen from
expressing its full effects on target tissues
(Katzenellenbogen et al., 1979; Kurl & Borthwick,
1980). AntiE has been used in the treatment of
patients with breast cancer (Heuson et al., 1975). It
has also been shown recently to suppress both
hormone release and the growth of prolactin-
secreting pituitary tumours in rats (DeQuijida et al.,
1980) and in man (Lamberts et al., 1982). We have
reported in a recent study that the dopamine
agonist, 2-bromoergocriptine (CB-154), induced a
marked and concomitant suppression of mammary
and pituitary tumorigenesis in castrated male rats
given diethylstilboestrol (DES) and N-nitrosobutyl-
urea (NBU) (Sumi et al., 1983). Thus, the present
study was performed to investigate the influence of
antiE on tumorigenesis in the mammary and
pituitary glands and to clarify whether the anti-MT
effect of antiE is mainly due to impairment of
oestrogen-stimulated prolactin secretion or direct
blocking of the action of oestrogen on the
mammary gland.
We have also compared the inhibitory effects of
antiE and CB-154 on the development of MT.
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Materials and methods
A highly inbred strain of Wistar/Furth (WF) rats
maintained in our laboratory (Sumi et al., 1980)
was housed in a temperature (24+1°C) and light
(on at 7.00a.m., off at 6.00p.m.) controlled room
and given a standard commercial diet (Oriental MF
Ltd., Tokyo, Japan) and tap water. Castration was
performed under Somonopentyl (Sodium
pentobarbital; Pitman-Moore, Washington
Crossing, N.J.) anaesthesia administered i.p. Anti-
oestrogen (antiE) clomiphene citrate was provided
by Sionogi Research Laboratories, Sionogi & Co.,
Ltd. Tokyo, Japan). N-nitrosobutylurea (NBU) was
kindly supplied by Dr. M. Nakadate, National
Institute of Hygienic Sciences (Tokyo, Japan). A
pellet containing either 5.0mg diethylstilboestrol
(DES) and 45.0mg cholesterol, or 5.0mg antiE
clomiphene citrate and 45.0mg paraffin was made
by fusion of both chemicals and separately grafted
s.c. on the upper or lower back of each rat. These
pellets were concurrently implanted and replaced
every 2 months throughout the experiment in order
to maintain continuous stimulation.
After castration at 40 days of age rats were
divided into 6 groups. Group 1 was given no
further treatment. Groups 3 and 5 received DES
pellets and groups 4 and 6 were given both DES
and antiE pellets at the same time. At 50-55 days
of age, groups 2, 5 and 6 were treated for 30 days
with 5.0mg NBU per day, dissolved in the drinking
water (250p.p.m. solution). This is a subthreshold
dose which, even in female rats, does not induce
MT (Yokoro et al., 1977).
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Moribund or dead rats during the experiment
were autopsied. One year after the initial NBU
treatment all surviving rats were killed. Mammary
and pituitary glands, their tumours, and other
major organs were removed, weighed, and fixed in
10% formalin and/or Bouin's solution. Paraffin
sections were routinely stained with H and E, and
examined histologically.
Rats that survived 6 months or more after the
initiation of NBU treatment were included in the
study. Each rat was identified by a numbered ear
tag. The anatomic location of each MT was
recorded with the nipples as reference points and
were palpated weekly. The average of the largest
diameter in 2 dimensions was chosen as the tumour
size. Pituitary glands that weighed >30mg as
proposed by Clifton & Meyer (1956), or with
macroscopically visible tumours were interpreted to
be PT as previously described (Sumi et al., 1983).
The incidences of mammary and pituitary tumours
were evaluated by x2 analysis. The mean weights of
body and pituitary gland, the mean number of
MT/rat or MT/rat with MT, and the mean latency
of MT were estimated by Student's t test.
Results
Incidence of mammary and pituitary tumours
The incidences of MT and PT in each group are
shown in Table I. No MT and PT were found in
castrated male rats or rats castrated and treated
with NBU alone. Only one MT and PT was found
in 12 rats given DES and AntiE, whereas 3 MT
and 7 PT were detected in 9 rats given DES alone.
The addition of NBU to DES-treated rats increased
the incidence of MT by 2.5 times over that in rats
given DES alone it did not change PT incidence.
Signif-icant synergism of NBU and DES was
observed in mammary tumorigenesis. Among 17
rats receiving DES and NBU, MT and PT were
induced in 4 and 2 rats when antiE was
administered. Therefore, the development of MT
and PT was markedly and concurrently affected by
antiE treatment.
Figure shows the cumulative incidences of MT
in groups 3 to 6. Most MT in groups 3 and 5
occurred during the later stage of the experiment.
The appearence of MT induced by DES alone or in
combination with NBU was suppressed by the
antiE treatment. The final incidence of MT was
lower in group 6 than in group 3. The onset and
the mean latency of MT, however, were not longer
in group 6, compared to group 5. AntiE treatment
did not delay the early appearence of MT, which
was greatly shortened by the combination of DES
and NBU.
Number and size of MT
The mean number of MT/rat was sharply reduced
Table I Incidences of MT and PT in castrateda and antiE-treated male WF rats given DES alone or in combination
with NBU.
No. of Type of No. of Latency No. of No. of rats rats (%) MT MT/rat ofMT rats (%
with No. Of with (mean day with Group Treatment Initial Effective MT AC FA MT/rat' MTh 4-S.E.) PT'd
1. Control 5 5 0 -- 0 2. NBUalone' 16 16 0 ---- 0
3. DES alonef 10 9 3(33) 8 0 0.9+0.5 2.7+0.7 336+ 16 7(78) 4. DE atE 13 12 1 (8) 2 0 0.2 2.0 342 1 (8)h
5. DES+NBU 20 17 15(88)h 60 0 3.5+0.5' 4.0+0.5i 233+l3k 12(71) 6. DES+antiE+NBU 20 17 4(24)' 5 3 0.5+0.3m 2.0+0.6 244+45 2(12)'
aRats were castrated at 40 days of age. "Effective no. of rats that lived more than 6 months after the initial NBU treatment.
'Mea value + se.
dEither a gland weighing >30mg or a macroscopically visible tumour.
'Rats were given 5.0mgNBU/day in drinking water for 30 days when 50-55 days of age.
fPellets containing 5.0mgDES were grafted s.c. on the upper back.
95.0mg antiE pellets were simultaneously treated with DES pellets on the lower back and these were replaced every 2 months.
"Different from group 3; P<0.005 (X2 analysis)
'Different from group 3, P<0.01 (Student's t test)
iDifferent from group 3; P<0.05 (Student's t test)
kDifferent from group 3; P <0.001I (Student's t test)
'Different from group 5; P <0.005 (X2 analysis)
'mDifferent from group 5; P<0.001 (Student's t test)EFFECTS OF ANTIOESTROGEN ON TUMORIGENESIS 781
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Figure 1 Cumulative incidences of MT in castrated
male WF rats given DES alone (group 3) (A); DES
and antiE (group 4) (A); DES and NBU (group 5) (0);
and DES, antiE, and NBU (group 6) (0).
in antiE-treated rats receiving DES and NBU
compared with that in control rats without antiE
(Table I). MT produced in group 6 were 5
adenocarcinomas (AC) and 3 fibroadenomas (FA).
Therefore, the mean number of AC/rat was
0.3+0.1. The mean number of MT/rat with MT
was not different between groups 5 and 6.
As indicated in the distribution of AC with
diameters >2 mm, most AC were observed as
multiple nodules of various sizes (Figure 2).
Compared to group 5, the number of AC in group
6 was significantly reduced in each size category,
especially in that below 10mm diameter. In group 4
no AC > 10mm was present. Therefore, antiE
treatment affected the growth of MT as well as the
development of MT.
Body andpituitary weights
The mean body weight was significantly reduced in
castrated male rats treated with NBU alone or DES
alone (203 +5 g, 178 + 10g), compared with
castrated control rats (260+ 13 g). On the other
hand, there were no differences between antiE-
treated rats given DES alone or in combination
with NBU (l77+6g, 162+6g) and each
corresponding control rat without antiE treatment
(178+10g, 165+165+5g). AntiE treatment did
not further affect the DES-induced decrease in the
body weight.
The relative pituitary weight and its distribution
in each size are shown in Figure 3. The mean
pituitary weight was reduced in groups 4 and 6 by
approximately 50 and 80% compared to those in
groups 3 and 5, respectively. The weight decreases
c
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Figure 2 Effect of antiE on number and size of AC in
castrated male WF rats given DES alone or in
combination with NBU. Rectangles in upper histogram are those for rats given DES alone (Cl), or
DES and antiE (EO), and rectangles on lower
histogram are for NBU-treated rats given DES ([l), or
DES and antiE (S).
by antiE treatment were similar to those found in
castrated rats or castrated rats given NBU alone.
AntiE treatment therefore, reveresed the increase in
the pituitary weight by DES treatment. All the
pituitary weights, except one case, were below
10mg per 100g body weight in group 4. None of
the pituitary glands that weighed over 20mg per 100g body weight were observed in group 6. The
reduction in the pituitary weight associated with
antiE treatment was related to the fall in the
occurrence of MT.
Histology ofpituitary gland
Most PT was usually haemorragic chromophobeadenomas in histologic classification.
Some cases of PT which weighed >30mg were
hyperplastic. The pituitary gland containing microadenoma was observed in an antiE-treated rat
receiving DES alone or in combination with NBU.
The appearance of the latter followed 2AC and
2 FA in the mammary glands.
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Figure 3 Distribution of pituitary weights of castrated
tumorous, 0: rats with MT, *.
Discussion
We have shown in this study that the concurrent
development of MT and PT induced by DES alone
or in combination with NBU was markedly and
concomitantly prevented when antiE treatment was
administered. N-nitrosobutylurea compounds have
been shown to be carcinogenic in the mammary
gland in several strains of female rats (Gullino et
al., 1975; Odashima, 1970). In this study the
amount of NBU was a subthreshold dose which
could not induce MT in castrated male rats or
female rats (Yokoro et al., 1977). In contrast, the
combination treatment of NBU and DES
significantly increased the development of MT but
not PT. These findings indicate that NBU and DES
act synergistically in the induction of MT in
castrated male rats. The anti-tumour effect of antiE
on the mammary gland could be more clearly
detected in rats given the combination of DES and
NBU than in rats given DES alone. Sharp changes
in the mean number of MT/rat and the number of
MT in small to large sizes were also observed in
those rats given the combination treatment.
Therefore, antiE treatment inhibited the growth of
MT as well as the development of MT.
AntiE has been thought to mimic oestrogenic
action in binding to receptor sites on the oestrogen
target tissues such as the uterus, vagina, and
mammary tumour, and to prevent oestrogen from
male WF rats treated variously: tumorous, 0; non-
expressing its full effect on these tissues
(Katzenellenbogen et al., 1979; Kurl & Borthwick,
1980). Meanwhile, oestrogen stimulates prolactin
secretion in vivo (Chen & Meites, 1970; Gala &
Boss, 1975) and in vitro (Lu et al., 1971; Nicoll &
Meites, 1962). The pituitary gland and prolactin-
secreting pituitary tumour bind oestradiol (Kato et
al., 1968; Noteboom et al., 1982; Notides, 1970). In
this study a close parallel correlation between antiE
treatment and anti-oestrogenic events in the
mammary and the pituitary glands could be seen.
AntiE treatment was effective in reducing the
incidence of PT and the pituitary weight. Although
serum prolactin levels were not measured in this
study, we have recently shown that there is a
positive association between the DES-mediated
prolactin levels and PT and MT development.
Thus, the anti-MT effect of antiE was considered to
be due to the declining serum prolactin levels
caused by the prevention of DES-induced PT
formation. This is also supported by recent findings
of DeQuijida et al., (1980) that the antiE
compound, tamoxifen, has an inhibitory effect on
the growth of transplantable prolactin-secreting rat
pituitary tumour 7315 and its effect was
accompanied by a decrease in the level of
circulating prolactin. In contrast, a lack of
inhibitory effect of antiE on oestrogen-stimulated
prolactin secretion has been reported (Jordan &
Koerner 1976). However, Kurl & Morris (1978)EFFECTS OF ANTIOESTROGEN ON TUMORIGENESIS 783
showed differential depletion of cytoplasmic high
affinity oestrogen receptors after in vivo treatment
with clomiphene and tamoxifen, suggesting different
penetration capabilities. Thus, this discrepancy may
be related to differences in such capabilities among
antiE compounds or to variables such as dose,
mode and period of administration. AntiE might
have also contributed by directly impairing
oestrogen receptors in the mammary gland so as to
render the tissue insensitive to DES stimuli, but this
seems not to be the primary effect in this study.
We have provided evidence in the present and
previous studies (Sumi et al., 1983) that the
induction of MT and PT can be controlled in rats
under the influence of oestrogen stimuli by
prolonged treatment with the dopamine agonist 2-
bromoergocryptine (CB-154), or with the oestrogen
antagonist, clomiphene citrate. Although it may be
difficult to define the relative efficiency of these
treatments on anti-MT, both treatments applied to
rats given DES and NBU exhibited a similar effect
on the pituitary gland. However, a few differences
were observed. Since MT produced in CB-154-
treated and castrated rats that had been given DES
and NBU were mostly FA, AC incidence was only
1/20 (5%) (Sumi et al., 1983), as opposed to 4/17
(24%) in antiE-treated rats given DES and NBU.
Moreover, the onset and the mean latency of MT
in antiE-treated group were -5 months earlier and
3 months shorter, respectively, in spite of - 1.5
months earlier commencement of antiE treatment
than CB-154 treatment. Thus, CB-154 appears to
be more efficient in anti-mammary tumorigenesis
than antiE. The lack of appreciable effect on the
early onset of MT or the lack of complete blockade
of AC may be relevant to the property of antiE
that can exhibit both antagonistic and agonistic
actions (Bowman et al., 1981; Katzellenbogen et al.,
1979). Oestrogen produces a direct stimulatory
effect and indirectly stimulates DNA synthesis of
mammary epithelial cells through hypersecretion of
prolactin (Nagasawa et al., 1976). Both actions thus
promote the interaction of the target tissues to
carcinogens. As shown in our previous study (Sumi
et al., 1980), DES treatment is a prerequisite for
male mammary tumorigenesis, by feminizing the
mammary gland of castrated male rats. Therefore,
antagonistic effect of antiE might have been
insufficient during an earlier phase when DES
treatment conceivably acts to render cells more
susceptible to NBU treatment.
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